

EXAMINER'S AMENDMENT


1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Marc Cohen on 8/19/2009.

The application has been amended as follows:

DELETE all pending claims and in their place INSERT

--42. A compound of the formula



I

or pharmaceutically acceptable salts, thereof in which

R¹ is H;

R² is; optionally substituted phenyl; optionally substituted naphthyl; optionally substituted tetrahydronaphthyl; optionally substituted biphenyl; optionally substituted

Art Unit: 1625

heterocyclyl; COR⁶; CSR⁶; CN; (CH₂)NR⁹R¹⁰; HCNOR⁹; HCNNR⁹R¹⁰; OR¹¹; SR¹¹; NR¹¹R¹² or SO₂NR¹³R¹⁴;

R⁶ is H, C₁₋₆ alkyl, optionally substituted C₂₋₆ alkenyl, hydroxy, optionally substituted aryl, optionally substituted heterocyclyl, SR⁷ or NR⁷R⁸;
R⁷ and R⁸ are either the same or different and selected from H, optionally substituted C₁₋₆ alkyl, optionally substituted C₂₋₆ alkenyl, optionally substituted aryl and optionally substituted heterocyclyl;

R⁹ is H, optionally substituted C₁₋₆ alkyl, optionally substituted C₂₋₆ alkenyl, optionally substituted aryl or optionally substituted heterocyclyl;
R¹⁰ is hydrogen, methyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, neopentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, optionally substituted C₂₋₆ alkenyl, optionally substituted aryl or optionally substituted heterocyclyl;

R¹¹ is H, optionally substituted C₁₋₆ alkyl, optionally substituted C₂₋₆ alkenyl, optionally substituted aryl or optionally substituted heterocyclyl or together with R¹² form optionally substituted heterocyclyl;

R¹² is optionally substituted C₁₋₆ alkyl, optionally substituted C₂₋₆ alkenyl, optionally substituted aryl or optionally substituted heterocyclyl or together with R¹¹ form optionally substituted heterocyclyl;

Art Unit: 1625


R^3 , R and R' are either the same or different and selected from H, optionally substituted C₁₋₆ alkyl, optionally substituted C₂₋₆ alkenyl, optionally substituted C₁₋₆ alkoxy, optionally substituted acyl, hydroxy, optionally substituted amino, optionally substituted thio, optionally substituted sulphonyl, optionally substituted sulphanyl, optionally substituted sulphonylamino, halo, SO₃H, amine, CN, CF₃, optionally substituted aryl and optionally substituted heterocycl; and

R^4 and R^5 are chloro,


wherein the optional substituent is C₁₋₆ alkyl, CF₃, fluorine, chlorine, iodine, cyano, C₁₋₆ alkoxy, 5 or 6-membered aryl, heteroaryl, amino or C₁₋₆ alkylamino.

43. The compound according to Claim 42 in which either R² is optionally substituted phenyl, optionally substituted naphthyl, optionally substituted tetrahydronaphthyl, optionally substituted biphenyl, optionally substituted heterocycl, CH₂NR⁹R¹⁰ or COR⁶ or at least one of R, R³ and R' is optionally substituted C₁₋₆ alkyl, optionally substituted aryl, optionally substituted heterocycl, CH₂NR⁹R¹⁰ or COR⁶ in which R⁶ is NR⁷R⁸ or NR¹¹R¹².


44. A compound of the formula




PBT 1038




PBT 1050




PBT 1052



PBT 1033




PBT 1056




PBT 1051

Art Unit: 1625



or pharmaceutically acceptable salts, thereof.

45. The compound according to Claim 44 having the formula



or pharmaceutically acceptable salts, thereof.

46. A pharmaceutical composition comprising a therapeutically effective amount of a compound according any one of Claims 42, 44 or 45 in association with a pharmaceutically acceptable carrier.

Art Unit: 1625

47. The pharmaceutical composition according to Claim 46 which additionally comprises a medicament, said medicament being an inhibitor of the acetyl cholinesterase active site, an antioxidant, an anti-inflammatory agent or an estrogenic agent.

48. A hydrate of the compound of Claim 42.

49. A hydrate of the compound of Claim 44.

50. A hydrate of the compound of Claim 45. --

2. The following is an examiner's statement of reasons for allowance: The originally filed claims from the PCT parent were numbered 1-41. Subsequent amendments started at claim 29. This amendment does not change the originally allowed claims but puts the claims for allowance in clear form.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to D. Margaret Seaman whose telephone number is 571-272-0694. The examiner can normally be reached on 730am-4pm, Monday-Thursday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres can be reached on 571-272-0867. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

D. Margaret Seaman
Primary Examiner
Art Unit 1625

/D. Margaret Seaman/
Primary Examiner, Art Unit 1625